Section 21.05 of the Patent Act presently states that the quantity of the pharmaceutical product that can be authorized for export--so that's manufactured and sent--to an importing country, may not be more than the amount that the importing country stated in its notification. Again, it ties CAMR back to this WTO decision, this WTO waiver, that it was founded upon. In that decision it was specifically stated that the country that needed a particular amount of drug would say so in their notification to the WTO, and CAMR was developed to respond to that need. In our process, section 25.01 of the act says that you cannot export, under this special regime, more than the importing country specifically stated it needed.
On November 1st, 2010. See this statement in context.